Global Antimicrobial Resistance Surveillance Market Size Expands at Steady CAGR of 5.6% During 2023–2029 to Touch USD 7.92 Billion by 2029

Published | 20 December 2023

Global Antimicrobial Resistance Surveillance Market is flourishing because of increasing adoption of innovative diagnostic technologies to diagnose and treat growing incidences of hospital-acquired infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antimicrobial Resistance Surveillance Market size at USD 5.71 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Antimicrobial Resistance Surveillance Market size to grow at a CAGR of 5.6% reaching a value of USD 7.92 billion by 2029. Major growth drivers for the Global Antimicrobial Resistance Surveillance Market include an increasing incidence of infections attributed to drug-resistant pathogens, advancements in diagnostic technologies, a rising concern over antimicrobial resistance, governmental efforts to address antimicrobial resistance, and the emergence of multi-drug resistance linked to drug abuse. Notably, advanced imaging technologies now deliver clinical information swiftly, contrasting with traditional culture-based methods taking up to 48 hours for susceptibility data. The emergence of new techniques detecting drug resistance without lengthy culture processes shortens the diagnostic timeframe by at least a day. Faster and more advanced diagnostic tests are expected to drive growth in the antimicrobial resistance diagnostics market. Also, nosocomial infections, acquired during hospitalization, encompass diverse illnesses. Hospital-acquired infections, such as central line-associated bloodstream infections and urinary tract infections from catheters, are widespread. The prevalence of these infections is poised to boost the antimicrobial resistance diagnostics market, reflecting the growing use of invasive techniques and equipment in modern healthcare. However, high costs associated with antimicrobial resistance surveillance system and kits and technical challenges in the end-user are anticipated to restrain the overall market growth during the forecast period.

Opportunity – Initiatives to Increase Awareness about Antimicrobial Resistance and Control

Antimicrobial resistance (AMR) is a pervasive global threat to human health, prompting a unified response through the Global Action Plan for AMR (GAP-AMR) in 2015. The initiative aims to ensure sustained success in treating infectious diseases by providing effective, safe, and quality-assured medicines responsibly. Surveillance, led by the Global Antimicrobial Resistance and Use Surveillance System (GLASS), is pivotal for policy formulation and infection control. GLASS standardizes data collection, analysis, and interpretation, promoting a shift towards comprehensive surveillance encompassing epidemiological, clinical, and population-level data. It actively engages in capacity building and partners with WHO and regional networks to bridge knowledge gaps and inform strategies, contributing significantly to global AMR awareness initiatives.

Sample Request @ https://www.blueweaveconsulting.com/report/antimicrobial-resistance-surveillance-market/report-sample

Impact of Covid-19 on Global Antimicrobial Resistance Surveillance Market

Covid-19 pandemic had a positive impact on Global Antimicrobial Resistance Surveillance Market. Several factors contributed to this exacerbation, including heightened antibiotic use for COVID-19 patients, disruptions in infection control measures within overwhelmed healthcare systems, and the redirection of resources away from monitoring and addressing antimicrobial resistance (AMR) threats. The pandemic necessitated the adoption of virtual visits and rapid diagnostic testing to minimize hospital visits. Even post-pandemic, home-based healthcare is expected to remain essential, particularly for individuals with pre-existing conditions, thereby fueling the demand for diagnostic assays.

Global Antimicrobial Resistance Surveillance Market – By End User

On the basis of end user, the Global Antimicrobial Resistance Surveillance Market is split into Hospitals & Clinics and Research & Academic Institutes segments. The hospitals & clinics segment holds a higher share in the Global Antimicrobial Resistance Surveillance Market by end user, primarily due to the elevated patient density observed in hospitals and clinics, the rising incidence of nosocomial infections within hospital settings, and the imperative to uphold stringent infection control protocols.

Global Antimicrobial Resistance Surveillance Market – By Region

The in-depth research report on the Global Antimicrobial Resistance Surveillance Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Antimicrobial Resistance Surveillance Market. The region's dominance is attributed to its well-established healthcare systems and advanced laboratory facilities in the United States and Canada. These major countries exhibit substantial investments in antimicrobial resistance (AMR) surveillance, with a specific focus on clinical diagnostics and data collection. The region's robust healthcare infrastructure and high standards of patient care contribute to the significant share held by clinical diagnostics in North America. Notably, the Centers for Disease Control and Prevention (CDC) in the United States spearhead AMR surveillance efforts. Meanwhile, the Asia Pacific region is expected to witness the fastest growth rate during the forecast period. China, in particular, has made noteworthy investments in AMR surveillance, establishing a national data collection network. Collaboration with international organizations, such as the World Health Organization (WHO), further enhances the region's efforts. The Asia Pacific region, encompassing diverse healthcare systems and population sizes, including China and India, encounters distinct challenges, prompting an upsurge in public health surveillance initiatives facilitated by regional and global health organizations.

Competitive Landscape

Major players operating in the Global Antimicrobial Resistance Surveillance Market include Becton, Dickinson and Company, Biomerieux, Thermo Fisher Scientific, Danaher, Luminex Corporation, Bruker, Bio-Rad, Qiagen, Abbott Laboratories, Roche Diagnostics, OpGen, Inc., Wolters Kluwer N.V., Lumed, BioSpace, and Cepheid. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Don’t miss the business opportunity in the Global Antimicrobial Resistance Surveillance Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Resistance Surveillance Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Resistance Surveillance Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com